Search

Displaying results 4101 - 4110 of 6076 in total
  1. Drug

    PEG-uricase

    go.drugbank.com/drugs/DB05321
    Investigational

    PEG-uricase, a polyethylene glycol ("PEG") conjugate of recombinant porcine uricase (urate oxidase), which breaks down the uric acid deposits is being studied in Phase III clinical trials for the treatment

  2. Drug

    Bifidobacterium Longum Infantis 35624

    go.drugbank.com/drugs/DB17871
    Experimental

    Bifidobacterium Longum Infantis 35624 is a probiotic being investigated for the treatment of gastrointestinal disorders, such as Crohn's disease and irritable bowel syndrome.[A259872, A259877]

  3. Drug

    KT-A261

    go.drugbank.com/drugs/DB19317
    Experimental

    It is being investigated for the treatment of noninfectious uveitis.

  4. Drug

    PD-0299685

    go.drugbank.com/drugs/DB15264
    Investigational

    PD-0299685 is under investigation in clinical trial NCT00314964 (Study Evaluating PD-0299685 for the Treatment of Vasomotor Symptoms (Hot Flashes / Flushes) Associated With Menopause).

  5. Drug

    CXD101

    go.drugbank.com/drugs/DB16182
    Investigational

    CXD101 is under investigation in clinical trial NCT03873025 (A Study of CXD101 in Combination With Pembrolizumab for Relapsed or Refractory Diffuse Large B-cell Lymphoma).

  6. Drug

    MLN8054

    go.drugbank.com/drugs/DB13061
    Investigational

    MLN8054 has been used in trials studying the treatment of Colon Neoplasm, Breast Neoplasm, Bladder Neoplasm, Pancreatic Neoplasm, and Advanced Malignancies.

  7. Drug

    Clevudine

    go.drugbank.com/drugs/DB06683
    Investigational

    Categories: Antivirals for Systemic Use, Antiinfectives for Systemic Use
  8. Drug

    AZD0947

    go.drugbank.com/drugs/DB04848
    Experimental

    AZD0947 is a K+ channel opener, which was under investigation by AstraZeneca for the treatment of overactive bladder.

  9. Drug

    LY2275796

    go.drugbank.com/drugs/DB05165
    Investigational

    LY2275796 is a second-generation antisense anti-cancer drug candidate for clinical development.

  10. Drug

    Leflunomide

    go.drugbank.com/drugs/DB01097
    ApprovedInvestigational

    Leflunomide is a pyrimidine synthesis inhibitor belonging to the DMARD (disease-modifying antirheumatic drug) class of drugs, which are chemically and pharmacologically very heterogeneous. Leflunomide was approved by FDA and in many othe...